Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart disease study probes immune cell 'Recycling' in arteries

NCT ID NCT05708547

Knowledge-focused Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examined how immune cells change in people with coronary atherosclerosis (hardening of the arteries). Researchers compared blood and heart tissue samples from 61 patients undergoing heart surgery—some with coronary artery disease and some without. The goal was to see if a process called mitophagy (how cells recycle their energy centers) differs between the two groups, which could lead to a simple blood test for immune reprogramming in heart disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

61 people

The number who actually took part.

Started

Nov 2023

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Atheromatous coronary patients and non-coronary patients

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Person who provides oral consent Group 1: \- Patient scheduled for cardiac bypass surgery (isolated procedure) with extracorporeal circulation Group 2: * Patient scheduled for valve ou ascending aorta surgery with extracorporeal circulation * No coronary lesion * No peripheral arterial disease (limbs, carotids, aortic aneurysm) Exclusion Criteria: * Person not affiliated with national health care system * Medication that alters mitochondrial function (Chloroquine, hydroxychloroquine, rapamycin, carbamazepine, resveratrol, sildenafil) * Person under a legal protection measure (curatorship, guardianship, tutorship) * Pregnant, parturient or breastfeeding women * Major unable to express consent * Minor

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary atherosclerosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder coronary atherosclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary atherosclerosis

Contacts and locations

Locations

  • Chu Dijon Bourgogne

    Dijon, 21000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.